TherapeuticsMD, Inc. Files 10-Q for Period Ended March 31, 2024
Ticker: TXMD · Form: 10-Q · Filed: May 10, 2024 · CIK: 25743
Sentiment: neutral
Topics: 10-Q, TherapeuticsMD, SEC Filing, Quarterly Report, TXMD
TL;DR
<b>TherapeuticsMD, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, confirming its status as a smaller reporting company and compliance with SEC filing requirements.</b>
AI Summary
TherapeuticsMD, Inc. (TXMD) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. TherapeuticsMD, Inc. filed a 10-Q report for the quarterly period ended March 31, 2024. The company is registered with the SEC under the 1934 Act. Common stock of TherapeuticsMD, Inc. trades under the symbol TXMD on The Nasdaq Stock Market LLC. The company has elected to be treated as a smaller reporting company. TherapeuticsMD, Inc. has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.
Why It Matters
For investors and stakeholders tracking TherapeuticsMD, Inc., this filing contains several important signals. This filing provides an update on the company's financial performance and operational status for the first quarter of 2024. As a smaller reporting company, TherapeuticsMD, Inc. may have different disclosure requirements compared to larger filers, impacting how investors assess its financial health.
Risk Assessment
Risk Level: low — TherapeuticsMD, Inc. shows low risk based on this filing. The filing is a routine 10-Q report, indicating standard compliance procedures rather than significant new developments or risks.
Analyst Insight
Monitor future 10-Q filings for detailed financial performance, revenue trends, and any strategic updates from TherapeuticsMD, Inc.
Key Numbers
- 20240331 — Quarterly Period End Date (The report covers the period ending March 31, 2024.)
- 001-00100 — Commission File Number (SEC Commission File Number for TherapeuticsMD, Inc.)
- 87-0233535 — IRS Number (Internal Revenue Service Employer Identification Number.)
- 33431 — ZIP Code (Business Address ZIP Code.)
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant name
- 0001213900-24-041738 (other) — Accession Number
- 20240331 (date) — Conformed Period of Report
- 20240510 (date) — Filed as of Date
- TXMD (ticker) — Trading symbol for Common Stock
- The Nasdaq Stock Market LLC (company) — Exchange where Common Stock is registered
- 951 YAMATO ROAD, SUITE 220 (address) — Business Address
- BOCA RATON (location) — Business Address City
FAQ
When did TherapeuticsMD, Inc. file this 10-Q?
TherapeuticsMD, Inc. filed this Quarterly Report (10-Q) with the SEC on May 10, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by TherapeuticsMD, Inc. (TXMD).
Where can I read the original 10-Q filing from TherapeuticsMD, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by TherapeuticsMD, Inc..
What are the key takeaways from TherapeuticsMD, Inc.'s 10-Q?
TherapeuticsMD, Inc. filed this 10-Q on May 10, 2024. Key takeaways: TherapeuticsMD, Inc. filed a 10-Q report for the quarterly period ended March 31, 2024.. The company is registered with the SEC under the 1934 Act.. Common stock of TherapeuticsMD, Inc. trades under the symbol TXMD on The Nasdaq Stock Market LLC..
Is TherapeuticsMD, Inc. a risky investment based on this filing?
Based on this 10-Q, TherapeuticsMD, Inc. presents a relatively low-risk profile. The filing is a routine 10-Q report, indicating standard compliance procedures rather than significant new developments or risks.
What should investors do after reading TherapeuticsMD, Inc.'s 10-Q?
Monitor future 10-Q filings for detailed financial performance, revenue trends, and any strategic updates from TherapeuticsMD, Inc. The overall sentiment from this filing is neutral.
How does TherapeuticsMD, Inc. compare to its industry peers?
TherapeuticsMD, Inc. operates in the pharmaceutical preparations industry.
Are there regulatory concerns for TherapeuticsMD, Inc.?
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing quarterly reports (10-Q).
Industry Context
TherapeuticsMD, Inc. operates in the pharmaceutical preparations industry.
Regulatory Implications
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing quarterly reports (10-Q).
What Investors Should Do
- Review the full 10-Q filing for detailed financial statements and management discussion.
- Track future SEC filings for updates on the company's strategic direction and financial health.
- Analyze the company's performance against industry benchmarks and competitors.
Year-Over-Year Comparison
This is the 10-Q filing for the quarter ended March 31, 2024. No comparative data from a prior filing is presented in this header information.
Filing Stats: 4,519 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2024-05-10 16:18:59
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Market
Filing Documents
- ea0205049-10q_therapeutics.htm (10-Q) — 456KB
- ea020504901ex31-1_therap.htm (EX-31.1) — 10KB
- ea020504901ex31-2_therap.htm (EX-31.2) — 10KB
- ea020504901ex32-1_therap.htm (EX-32.1) — 4KB
- ea020504901ex32-2_therap.htm (EX-32.2) — 4KB
- 0001213900-24-041738.txt ( ) — 3913KB
- txmd-20240331.xsd (EX-101.SCH) — 49KB
- txmd-20240331_cal.xml (EX-101.CAL) — 39KB
- txmd-20240331_def.xml (EX-101.DEF) — 216KB
- txmd-20240331_lab.xml (EX-101.LAB) — 387KB
- txmd-20240331_pre.xml (EX-101.PRE) — 215KB
- ea0205049-10q_therapeutics_htm.xml (XML) — 362KB
- Financial Information
Part I - Financial Information Item 1.
Financial statements (unaudited)
Financial statements (unaudited) Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.
Management's discussion and analysis of financial condition and results of operations
Management's discussion and analysis of financial condition and results of operations 16 Item 3.
Quantitative and qualitative disclosures about market risk
Quantitative and qualitative disclosures about market risk 24 Item 4.
Controls and procedures
Controls and procedures 24
- Other Information
Part II - Other Information Item 1.
Legal proceedings
Legal proceedings 25 Item 1A.
Risk factors
Risk factors 25 Item 2. Unregistered sales of equity securities and use of proceeds 25 Item 3. Defaults upon senior securities 25 Item 4. Mine safety disclosures 25 Item 5. Other information 25 Item 6. Exhibits 26
Signatures
Signatures 27 i Part I - Financial Information Item 1. Financial statements TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except per share data) March 31, 2024 December 31, 2023 (Unaudited) Assets: Current assets: Cash and cash equivalents $ 4,338 $ 4,327 Royalty receivable, current portion 3,222 3,090 Prepaid and other current assets 3,869 4,035 Current assets of discontinued operations 94 344 Total current assets 11,523 11,796 License rights and other intangible assets, net 5,965 6,098 Right of use assets 6,687 6,873 Royalty receivable, long term 17,855 18,484 Other non-current assets 58 58 Total assets $ 42,088 $ 43,309 Liabilities and stockholders' equity: Current liabilities: Accounts payable $ 139 $ 27 Accrued expenses and other current liabilities 2,720 3,133 Current liabilities of discontinued operations 3,609 3,694 Total current liabilities 6,468 6,854 Operating lease liabilities 6,319 6,532 Other non-current liabilities 637 636 Total liabilities 13,424 14,022 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value $ 0.001 ; 32,000 shares authorized, 11,532 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 11 11 Additional paid-in capital 979,028 978,917 Accumulated deficit ( 950,375 ) ( 949,641 ) Total stockholders' equity 28,664 29,287 Total liabilities and stockholders' equity $ 42,088 $ 43,309 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited - in thousands, except per share data) Three Months Ended March 31, 2024 2023 Revenue, net: License and service revenue $ 313 $ 416 Operating expenses: Selling, general and administrative 1,322 3,056 Depreciation & amortizati